Last update Oct. 9, 2016

Noscapine

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Centrally acting cough suppressor with properties and usage similar to dextromethorphan.

Its high plasma protein-binding capacity explains the observed negligible excretion into milk (Olsson 1986) and also because its low oral bioavailability the passage to infant plasma from ingested milk may be hindered.

American Academy of Pediatrics: medication usually compatible with breastfeeding.

Alternatives

We do not have alternatives for Noscapine since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Noscapine is also known as


Noscapine in other languages or writings:

Group

Noscapine belongs to this group or family:

Tradenames

Main tradenames from several countries containing Noscapine in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 30 %
Molecular weight 413 daltons
Protein Binding 93 %
VD 4.7 l/Kg
Tmax 2.5 hours
2.6 - 4.5 hours
M/P ratio 0.15 - 0.88 -
Theoretical Dose 0.002 - 0.01 mg/Kg/d
Relative Dose 0.07 - 0.8 %

References

  1. AAP - American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001 Sep;108(3):776-89. Abstract Full text (link to original source) Full text (in our servers)
  2. Karlsson MO, Dahlström B, Eckernäs SA, Johansson M, Alm AT. Pharmacokinetics of oral noscapine. Eur J Clin Pharmacol. 1990 Abstract
  3. Karlsson MO, Dahlström B. Serum protein binding of noscapine: influence of a reversible hydrolysis. J Pharm Pharmacol. 1990 Abstract
  4. Olsson B, Bolme P, Dahlström B, Marcus C. Excretion of noscapine in human breast milk. Eur J Clin Pharmacol. 1986 Abstract
  5. Dahlström B, Mellstrand T, Löfdahl CG, Johansson M. Pharmacokinetic properties of noscapine. Eur J Clin Pharmacol. 1982 Abstract

Total visits

31,986

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM